Tandem Therapeutics is a Swiss biopharmaceutical company on a mission to Unlocking the matrix barrier to treat fibrotic diseases. Leveraging over 15 years of research and development at ETH Zürich and Paul Scherrer Institut, the company focuses on pioneering precision targeting approaches to fibrosis and fibrotic cancers. Tandem Therapeutics' therapeutic platform is centered around Matrix Targeting Peptides (MTP) designed to conditionally target disease-associated matrix alterations directly linked to various fibrotic diseases. The company secured its last Fr.150.00K grant investment from Venture Kick on 24 February 2023. Based in Switzerland and founded in 2023, Tandem Therapeutics is poised to make significant strides in the treatment of fibrotic diseases.
Tandem Therapeutics
Unlocking the matrix barrier to treat fibrotic diseases
Schlieren, Switzerland
5 employees
Non Equity Assistance
Total: $150.00K
Health and Wellness
General Information
Get notified when Tandem Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Tandem Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Switzerland Market
Health and Wellness
About Tandem Therapeutics
Taxonomy: biopharmaceutical company, fibrotic diseases, precision targeting, fibrosis, extracellular matrix, Matrix Targeting Peptides, therapeutic platform, ETH Zürich, Paul Scherrer Institut, organ fibrosis, cancer treatment, Swiss, discovery stage, transformative research
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | •••••• | 1 |
|
19 Apr 2024 |
| Grant | •••••• | 1 |
|
24 Feb 2023 |
Tandem Therapeutics Alternatives & Competitors
We contribute to healthcare by developing novel radiopharmaceuticals for fibrotic diseases.
Syntara (ASX:SNT) is an ASX-listed clinical stage drug developer for diseases linked to fibrosis and...
We develop breakthrough treatments for Claudin1-positive tumors and organ fibrosis
FAQ About Tandem Therapeutics
Don't just browse. Track.
Signal Tracker monitors Tandem Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.